IFNG and liver cancer: Scott W. Lowe’s group found that senescent liver cancer cells upregulated the receptors of type II interferons (IFN-gamma) to become hypersensitive to IFN-gamma, which activated its downstream signals and enhanced the antigen process and presentation on MHC-I molecules, leading to a more “visible” feature of these senescent liver cells to immunosurveillance in vivo [150].